2fx9: Difference between revisions

From Proteopedia
Jump to navigationJump to search
← Older editNewer edit →
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,329,943 edits
No edit summary
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,329,943 edits
No edit summary
Line 1: Line 1:
[[Image:2fx9.gif|left|200px]]
{{Seed}}
[[Image:2fx9.png|left|200px]]


<!--
<!--
Line 9: Line 10:
{{STRUCTURE_2fx9|  PDB=2fx9  |  SCENE=  }}  
{{STRUCTURE_2fx9|  PDB=2fx9  |  SCENE=  }}  


'''Crystal structure of hiv-1 neutralizing human fab 4e10 in complex with a thioether-linked peptide encompassing the 4e10 epitope on gp41'''
===Crystal structure of hiv-1 neutralizing human fab 4e10 in complex with a thioether-linked peptide encompassing the 4e10 epitope on gp41===




==Overview==
<!--  
Potent, broadly HIV-1 neutralizing antibodies (nAbs) may be invaluable for the design of an AIDS vaccine. 4E10 is the broadest HIV-1 nAb known to date and recognizes a contiguous and highly conserved helical epitope in the membrane-proximal region of gp41. The 4E10 epitope is thus an excellent target for vaccine design as it is also highly amenable to peptide engineering to enhance its helical character. To investigate the structural effect of both increasing the peptide length and of introducing helix-promoting constraints in the 4E10 epitope, we have determined crystal structures of Fab 4E10 bound to an optimized peptide epitope (NWFDITNWLWYIKKKK-NH(2)), an Aib-constrained peptide epitope (NWFDITNAibLWRR-NH(2)), and a thioether-linked peptide (NWFCITOWLWKKKK-NH(2)) to resolutions of 1.7 A, 2.1 A, and 2.2 A, respectively. The thioether-linked peptide is the first reported structure of a cyclic tethered helical peptide bound to an antibody. The introduced helix constraints limit the conformational flexibility of the peptides without affecting interactions with 4E10. The substantial increase in affinity (10 nM versus 10(4) nM of the IC(50) of the original KGND peptide template) is largely realized by 4E10 interaction with an additional helical turn at the peptide C terminus that includes Leu679 and Trp680. Thus, the core 4E10 epitope was extended and modified to a WFX(I/L)(T/S)XX(L/I)W motif, where X does not play a major role in 4E10 binding and can be used to introduce helical-promoting constraints in the peptide epitope.
The line below this paragraph, {{ABSTRACT_PUBMED_17125793}}, adds the Publication Abstract to the page
(as it appears on PubMed at http://www.pubmed.gov), where 17125793 is the PubMed ID number.
-->
{{ABSTRACT_PUBMED_17125793}}


==About this Structure==
==About this Structure==
Line 20: Line 24:
==Reference==
==Reference==
Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10., Cardoso RM, Brunel FM, Ferguson S, Zwick M, Burton DR, Dawson PE, Wilson IA, J Mol Biol. 2007 Feb 2;365(5):1533-44. Epub 2006 Nov 10. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/17125793 17125793]
Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10., Cardoso RM, Brunel FM, Ferguson S, Zwick M, Burton DR, Dawson PE, Wilson IA, J Mol Biol. 2007 Feb 2;365(5):1533-44. Epub 2006 Nov 10. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/17125793 17125793]
Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41., Cardoso RM, Zwick MB, Stanfield RL, Kunert R, Binley JM, Katinger H, Burton DR, Wilson IA, Immunity. 2005 Feb;22(2):163-73. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/15723805 15723805]
[[Category: Brunel, F M.]]
[[Category: Brunel, F M.]]
[[Category: Burton, D R.]]
[[Category: Burton, D R.]]
Line 29: Line 35:
[[Category: Beta-sandwich]]
[[Category: Beta-sandwich]]
[[Category: Immunoglobulin fold]]
[[Category: Immunoglobulin fold]]
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May  4 04:24:41 2008''
 
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Jul 27 16:59:04 2008''
Retrieved from "https://proteopedia.org/2fx9"